Faron Pharmaceuticals

In June 2022 and January 2023, LLS made equity investments in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indications."

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. 

The Phase 1/2 BEXMAB study (NCT05428969) investigates bexmarilimab in combination with azacitidine in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Patients are being enrolled at both US and Finland sites.

The Phase 2 part of the BEXMAB study in HMA-failed MDS patients is currently enrolling in the US and Finland (NCT05428969).Consistent with the FDA's Project Optimus initiative, the planned Phase 2 will start with dose optimization and is expected to enroll ~32 patients randomized between two selected doses. Faron plans to increase the number of US clinical sites from two to five sites to accelerate study recruitment. 

For more information about Faron, visit www.faron.com/.

Recent News

• August 27, 2024 - announced bexmarilimab has been granted Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine by the FDA
• July 11, 2024 - provided information on the result of its formal Type D Scientific Advice Meeting with the FDA regarding the registrational study plan for its drug candidate bexmarilimab in relapsed and refractory high risk MDS (r/r MDS).
• June 20, 2024 - announced the completion of the Offering of approximately EUR 30.7 million
• January 9, 2024 - announced first HMA-failed MDS patient was dosed with bexmarilimab as part of Phase 2 of BEXMAB trial
• October 11, 2023 - announced updated data from the Phase 1/2 BEXMAB study investigating bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs).
• January 27, 2023 - announced results of private placement, supported by new investors and existing shareholders including The Leukemia & Lymphoma Society Therapy Acceleration Program®
• June 28, 2022 - announced a private placement to a limited number of institutional and other investors to raise EUR 5 million including The Leukemia & Lymphoma Society Therapy Acceleration Program^® (LLS TAP).